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negative symptoms. The results suggest that functioning and improvement in
functioning are more strongly correlated with negative than with positive and
other symptom factors.
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OBJECTIVES: To examine the association of antidepressant-related weight gain
with degree of enjoyment and satisfaction from general daily activities, medication
and overall quality of life.METHODS: Employed individuals (18 years of age) with
depression (excluding bipolar disorder) completed a web-based computer-gener-
ated 25-minute survey (population identified by Harris Interactive). Weight gain
was measured using the Toronto Side Effects Scale which measures medication-
related side effects in the two weeks preceding the survey, and analyzed as a
4-level ordinal variable (none, 2lbs, 4lbs, 7lbs). Degree of enjoyment and
satisfaction related to general activities, satisfaction with current medication, and
overall quality of life were measured using a 5-point ordinal scale (1very poor;
5very good) employing the Quality of Life Enjoyment and Satisfaction Question-
naire – Short Form (QLESQ-SF). A summary “percent-of-max” score was calculated
for general activity items, and transformed to a 5-level ordinal variable using cut-
points of 20, 40, 60 and 80% (20% represented least overall enjoyment/satisfac-
tion) . Gender stratified cumulative logit models were used to estimate the effect of
weight gain on QLESQ-SF measures.RESULTS:Of the 1,521 survey respondents, 872
(57%) reported current antidepressant use (60.6% female, mean age 49.9  13.5
years). Compared to females with no weight gain, the odds of having lower enjoy-
ment/satisfaction were greater for females who experienced any weight gain:
2lbs (odds ratio [OR]2.22; p0.0001),4lbs (OR2.27; p0.004) and7lbs
(OR12.50; p0.0001). Among males lower QLESQ score was associated only with
the 7lbs category (OR5.26; p0.0004). Satisfaction with medication was in-
versely associated with weight gain for females; 2lbs (OR1.49; p0.051),
4lbs (OR2.33; p0.002) and 7lbs (OR8.33; p0.0001) and males; 7lbs
(OR2.78; p0.031). CONCLUSIONS: These data suggest that antidepressant-re-
lated weight gain may have strong associations with patient perceptions of dimin-
ished enjoyment and satisfaction in general daily activities and with current med-
ication, which may affect medication adherence.
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OBJECTIVES: The goal of this research was to compare the effect of donepezil oral
standard tablets (OST) versus donepezil oral disintegrating tablets (ODT) on stress
and objective burden in caregivers of de novo patients with dementia of AD in
routine medical practice. METHODS: A 6-month, prospective, observational study
enrolled naïve patients with possible/probable AD according to DSM-IV/NINCDS-
ADRDA criteria. Comparison on caregiver stress and objective burden was carried-
out between donepezil formulations of OST and ODT for a 6 month period. The
self-administered ZARIT scale and daily hours devoted to the care of patients on
basic and instrumental activities of daily-living (BADL, IADL), behaviour supervi-
sion and nursing home institutionalization were computed. RESULTS: 547 naïve
and de novo AD patients were analyzed: 123 (22.5%) received OST and 424 (77.5%)
ODT, at 7.1 (2.5) and 7.1 (2.6) mg/day, respectively. No significant differences were
observed in age, sex distribution, schooling, educational training, or relationship
with main caregiver between groups. Baseline clinical characteristics (comorbidi-
ties, symptoms of dementia duration, MMSE scoring) were homogeneous between
groups and remained unchanged during the study; Adjusted ZARIT scoring was
reduced significantly in ODT group by -1.1 point (p0.001) but this was not statis-
tically higher than the reduction observed in OST cohort; -0.5 (p0.527 between
groups comparison). Daily hours of care on BADL and IADL were not statistically
different between cohorts and remained unchanged during the study. Also, aver-
age number of hours/day on behaviour supervision or general supervision and the
percentage of caregivers having to quit their jobs were similar. CONCLUSIONS:
Findings of this study show that both subjective and objective burden of caregivers
of de novo patients with AD treated with donepezil remain stables during the
6-month period of the study, and it is unrelated with type of formulation given to
patients.
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OBJECTIVES: Patients with major depressive disorder (MDD) frequently report
lower quality of life (QoL) and increased disability compared with the general pop-
ulation. This post hoc analysis describes the association between QoL, painful
physical symptoms (PPS), depressive symptoms and employment status in a Chi-
nese MDD patient cohort. METHODS: Chinese MDD patients (299) from a prospec-
tive observational study of six East Asian countries/regions were compared at base-
line and after 3 months of naturalistic treatment on QoL (EuroQoL Questionnaire-5
Dimensions [EQ-5D] utility score), PPS (Somatic Symptom Inventory [SSI]), depres-
sion (17-item Hamilton Depression Rating Scale [HAMD17]) and employment sta-
tus measures. Patients were classified as PPS positive or negative (PPS, PPS-; SSI
mean score 2 or 2 respectively). Effect sizes (ES) were calculated using Cohen’s
d. RESULTS: Patients who were employed at baseline reported higher QoL (EQ-5D:
0.60 vs. 0.42; ES 0.7) and were less severely ill (HAMD17 total score: 22.7 vs. 26.0; ES
-0.7) than those who were unemployed. Few transitions in employment status
were observed during the study. Self-reported QoL was low (EQ-5D: mean 0.52) at
baseline and improved substantially after 3 months (EQ-5D: 0.89). PPS patients
were more severely ill (HAMD17: 25.4 vs. 23.3; ES 0.4) and had a lower QoL (EQ-5D:
0.41 vs. 0.58; ES -0.6) at baseline than PPS- patients. The higher illness severity
(HAMD17: 7.0 vs. 4.6; ES 0.4) and lower QoL (EQ-5D: 0.83 vs. 0.92; ES -0.6) of PPS
patients persisted after 3 months. CONCLUSIONS: Employed patients reported a
higher QoL and a lower symptomatic burden than unemployed patients. Patients
with a low QoL were more likely to be unemployed. The QoL of Chinese MDD
patients improved over 3 months of naturalistic treatment. The presence of PPS
was associated with higher illness severity and lower QoL at baseline and after 3
months.
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OBJECTIVES: Health-related Quality of Life (HRQoL) has become both a target of
intervention and a crucial outcome in evaluating treatment of alcohol dependence.
Little has been studied on the factors associated with HRQoL before alcohol depen-
dence treatment. We explored the association between HRQoL and several risk
factors including level of alcohol consumption. METHODS: We used data from
CONTROL, an observational cohort study on 143 alcohol dependent patients from
Lausanne hospital, Switzerland, followed for 12 months. Average daily alcohol
consumption was collected every month and categorised according to the World
Health Organisation’s risk levels (WRL) classification: high, medium, low or absti-
nent. Other measures were collected every three months: HRQoL (SF-36), Beck
inventory depression score (BDI) and sociodemographic characteristics. The mean
score for each dimension and for the Physical and Mental Component Summary
Score (PCS and MCS) were calculated at baseline and at 12-months. Correlates of
MCS and PCS were identified using Pearson correlation coefficients and factors
associated with change from baseline to 12-months were identified using linear
mixed models. RESULTS: At baseline, except for physical functioning, all average
SF-36 scores were below those in the general population. The most impaired scores
were those with the heavier contribution to MCS. MCS was significantly correlated
with BDI, WRL and age. Compared to abstinent patients, difference in MCS scores
was significantly lower in patients with medium (difference-12.9; p0.005) or
high risk (difference-14.8; p0.0001) levels whereas no significant difference was
observed between abstinent and low risk patients (difference-7.3; N.S.). Change in
MCS from baseline to 12-months was associated with BDI and WRL. No significant
association was found with PCS. CONCLUSIONS: HRQol is significantly in alcohol-
dependent patients. The level of alcohol consumption and depression appeared as
important drivers of HRQoL related to mental health.
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OBJECTIVES: To describe treatment characteristics among children with Attention
Deficit/Hyperactivity Disorder (ADHD) using atomoxetine in two European
countries. METHODS: Medical charts of patients aged 6-17 with 1 diagnosis of
ADHD between 1/2004-6/2007 were reviewed by physicians from 6 European coun-
tries. All patients had 2 years of follow-up data and received pharmacological or
behavioral therapy post-diagnosis, and were not enrolled in a clinical trial. This
analysis focused on two countries with the largest samples of Strattera® (atomox-
etine HCL) users: UK (UK) and Italy (IT). Outcomes presented include descriptive
statistics (means, rates, percentages) describing treatment: patterns, response and
satisfaction. RESULTS: 94 patients met inclusion criteria (UK [n51], IT [n43]).
Patients were predominantly male 80.4% (UK) and 76.7% (IT), Caucasian, 88.2% and
95.3% and mean (SD) age at diagnosis was 9.5(2.6) and 9.0(2.9). Most patients were
diagnosed via the Connors (76.5%) (UK) or DSM-IV (51.1%; IT) criteria. A majority of
patients presented as combined type ADHD (hyperactive/impulsive and inatten-
tive symptoms) (UK 74% and IT 62%). Between 63% to 76% of all patients indi-
cated 8 impairment for impulsivity and hyperactivity (scale from 0 “no impair-
ment” to 10 “high level impairment”). 76.5% (UK) and 55.8% (IT) of patients received
two or more ADHD treatments and 42.1% and 20.5% received a methylphenidate
product; 37.3% and 32.6% of physicians in the UK and IT, respectively, indicated
that these patients had a “poor” or “very poor” response to methylphenidate. 64.9%
of patients were currently prescribed atomoxetine vs. 35.1% previously prescribed.
23.0% of physicians of current patients indicated that they were “neither satisfied
nor dissatisfied,” “moderately dissatisfied,” or “very dissatisfied” with current ato-
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moxetine treatment. CONCLUSIONS: At baseline, country-level variations in some
patient characteristics were evident in children with ADHD treated with atomox-
etine in the UK and IT. Further, this study suggests an opportunity for improved
ADHD treatment response and satisfaction outcomes.
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OBJECTIVES: To understand the association of antidepressant-related weight gain
with various aspects of worker productivity.METHODS: Employed individuals (18
years of age) with diagnosed depression (excluding bipolar disorder) completed a
web-based computer-generated 25-minute survey (study population identified by
Harris Interactive). Weight gain was measured using the Toronto Side Effects Scale
which measures medication-related side effects in the 2-weeks preceding the sur-
vey, and was analyzed as a 4-level ordinal variable (none, 2lbs, 4lbs, and
7lbs), where “none” was the referent category. The Work Productivity and Ac-
tivity Impairment (WPAI) questionnaire was used to assess percent of impaired
productivity (overall, absenteeism, presenteeism, activity impairment) during the
2-weeks preceding the survey, with higher numbers indicating greater impairment
and less productivity (i.e., worse outcomes). Using distribution among current an-
tidepressant users, each WPAI measure was categorized into quintiles, with the
lowest and highest representing least and greatest impairment, respectively. Cu-
mulative logit models were used to estimate the overall effect of weight gain on
WPAI measures as well as across gender. RESULTS: Of the 1521 survey respon-
dents, 872 (57%) reported current antidepressant use (60.6% female, mean age 49.9
 13.5 years). Weight gain was associated with loss of productivity: 2lbs (odds
ratio [OR] 1.54; p0.005),4lbs (OR 2.14 ; p0.0007 ) and7lbs (OR 2.96; p
0.0009). In females, using “no weight gain” as a reference group, the odds of being
in a worse overall productivity category increased with the increase of weight gain:
2lbs (odds ratio [OR]1.59; p0.02), 4lbs (OR2.17; p0.005) and 7lbs
(OR3.13; p0.01). Similar trends were observed in males: 2lbs (OR1.43;
p0.15),4lbs (OR2.00; p0.06) and7lbs (OR2.86; p0.02). CONCLUSIONS:
In employees with depression, antidepressant-related weight gain was associated
with loss in overall productivity. Additional research to quantify the indirect costs
of antidepressant-related weight gain in terms of productivity losses may be use-
ful.
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STAY HEALTHY THROUGH GAME-CARE THERAPEUTICS: IT’S TIME TO PLAY
THE GAME!
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OBJECTIVES: Health care research in present scenario is a platform wherein a
range of interventions play their role to alleviate suffering and mitigate the course
of diseases. Gaming console have so far demonstrated promising and considerable
potential as rehabilitation and lifestyle treatments. The objective of this review
was to study the advent and role of new generation gaming consoles (e.g. Nintendo
Wii, Xbox, and PS3) in healthcare research in a systematic manner. METHODS: A
consolidated search strategy was developed and run in EMBASE, MEDLINE, Co-
chrane, POPLINE, SCOPUS, and Clinicaltrials.gov databases to identify the trials
utilising gaming consoles as principal intervention or supportive treatment in var-
ious disease areas. Grey literature was also identified though Google Scholar. Data
extraction was performed and results were summarized. RESULTS: The data re-
vealed that motion sensor and interactive gaming consoles have found their role in
multiple health care fields ranging from rehabilitation, weight loss, stroke recov-
ery, improvement in locomotor activity, Parkinson’s disease, Alzheimer’s disease,
and back pain, etc. Also, their active presence in promoting exercise, health care
coaching and monitoring, and health awareness programs has seen a marked
increase due to new and innovative applications being identified every day.
CONCLUSIONS: Newer health care technologies and platforms like gaming con-
soles help in numerous disease area to improve patient outcomes. Their transfor-
mation, propagation, and implementation as tools of healthcare services is a valu-
able strategy that the health care organizations should consider taking into
consideration the emerging field of gaming technology in parallel with health tech-
nology. Detailed analysis, data tables, and graphs describing the study results will
be presented.
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OBJECTIVES: Individuals with schizophrenia are found to receive poorer medical
care, and have a higher prevalence of diabetes than general population. Once a
hypoglycemic therapy is needed, proper compliance to the therapy and diabetic
care are important for achieving good glycemic control as well as preventing acute
complications. Therefore, this study aimed to compare diabetic care and risk of
acute complications after the initiation of the therapy for three years, between type
II diabetics with schizophrenia versus those without schizophrenia. METHODS:
This study used the claims database of the National Health Insurance program.
Enrollees who began oral hypoglycemic therapy in 2001, and had been diagnosed
with schizophrenia and refilled at least one prescription of antipsychotic(s) in the
year prior to the index date were included in the study (the case group). Enrollees
without schizophrenia who began oral hypoglycemic therapy in 2001 were selected
from a randomly selected sample of the enrollees to match the age and gender of
the case group (1:1) (the comparison group). Indicators of diabetic care included
good medication compliance (a medication possession ratio0.8), blood glucose
test, and HbA1c test. Indicators were measured annually. Acute complications
were defined as emergency room visits or hospital admissions due to coma, hypo-
glycemia, hyperglycemia, or diabetic ketoacidosis. Cox proportional hazards model
was adopted to assess risk of acute complications. RESULTS: There were 544 sub-
jects in the case group and comparison group, respectively. The percentage of
subjects compliant to the therapy in the case group was decreasing. In addition, the
case group had poorer blood glucose-related monitoring in the long run, and had a
higher risk of acute complications than the comparison group. CONCLUSIONS:
Diabetics with schizophrenia, compared with those without such a condition, had
worse diabetic care. Better disease management will be necessary for this patient
group.
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OBJECTIVES: Drug choice and adherence are important aspects in schizophrenia
and bipolar disorder (BD) and depend on patient and drug characteristics. Our aim
was to examine Nordic psychiatrists’ views on treatment choice, adherence, once
daily dosing (ODD), and the use of extended release (XR) and instant release (IR)
quetiapine.METHODS:We conducted a quantitative, telephone-based survey with
201 respondents randomly selected from a list of all 1906 Swedish and 677 Danish
psychiatrists (excluding child and geriatric psychiatrists). Structured, one-hour
qualitative interviews with 10 psychiatrists per country allowed us to further in-
terpret the results. Data was collected by an independent research company. For
binary variables, we performed a binomial test of the null hypothesis that the
alternative responses were equally likely. RESULTS: One hundred one Danish and
100 Swedish psychiatrists were included; 65% were male and the mean (SD) psy-
chiatric experience was 15.4 (8.2) years. No relevant country differences were
found. 198 psychiatrists (99%) agreed on the importance of individualized treat-
ment (p0.0001). Respondents reported that 42% of schizophrenia and 33% of BD
patients tried 3 antipsychotics before being stabilized. All respondents reported
non-adherence to be common and all associated non-adherence with side-effects.
199 (99%) psychiatrists thought that ODD would improve adherence (p0.0001),
and 196 (98%) that it could mitigate partial adherence problems (p0.0001). 179
respondents (89%) said that ODD reduces relapse rates (p0.0001). A total of 147
psychiatrists (73%) associated quetiapine XR with less day sedation than IR
(p0.0001), and 132 (66%) associated XR with a reduced need for injection treat-
ment (p0.0001). In the qualitative interviews, XR was to a higher extent associated
with antipsychotic monotherapy and IR more often with short-term use for e.g.,
sedation. CONCLUSIONS: Nordic psychiatrists considered individualized drug
therapies in schizophrenia and BD to be important and perceived ODD to improve
adherence. Respondents associated quetiapine XR with differential use compared
to IR.
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OBJECTIVES: This study was to estimate the national trend of physician-office
visits for patients with Alzheimer’s disease and senile dementia (ADSD), related
characteristics, primary payment source, and prescribed medications over a period
of 12 years (1998 – 2009) in the United States.METHODS: Physician-office visits with
ADSD diagnosis were identified in the National Ambulatory Medical Care Survey,
stratified by time frame, to perform a trend analysis for patients aged 40 with
relevant ICD-9-CM codes (290.xx, 294.xx, 331.xx). Main outcomes of interest are the
changes in ADSD physician-office visits, primary payer source, and prescribed
medications. A series of multivariate regressions (generalized linear model [GLM]
with Poisson distribution) for number of medications prescribed per visit were
employed by year to estimate the increased medication numbers associated with
ADSD, controlling for patient demographics, comorbidities, and visit/payment
characteristics. The impact of explanatory variables at both physician-office and
visit level was also assessed through hierarchical modeling. RESULTS: Over the
12-year period, the annual ADSD visits and average all-purpose medications pre-
scribed per ADSD visit have yearly growth rates of 18.2% and 10.7%, respectively.
Medicare has consistently been the largest primary payer for ADSD physician-
office visits (from 67% of visits in 1998 to 77% in 2009). Private payer and Medicaid
also have increased shares (from 6% to 13% and from 4% to 5%, respectively) as
primary payer, while fewer visit portions are primarily covered by Self-pay and
Other sources. Numbers of drug mentions per visit attributable to ADSD, esti-
mated through GLM regressions, are 0.64 in 1998, 1.92 in 2004, and 2.20 in 2009.
CONCLUSIONS: ADSD patients’ use of physician-office services has increased
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